Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)?
- PMID: 11769764
Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)?
Comment in
-
Rebuttal, evidence and debate.Int J Tuberc Lung Dis. 2003 Jan;7(1):100. Int J Tuberc Lung Dis. 2003. PMID: 12701844 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
